Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22341277 | 0.86 | FOLH1 (0.58) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL12987950 | 0.83 | ECE1 (0.44) | KMT2AFOLH1CA2CA1MME | |
| SCHEMBL13195868 | 0.83 | L3MBTL1 (0.49) | KMT2AALOX15 | |
| SCHEMBL28879483 | 0.83 | L3MBTL1 (0.49) | KMT2AALOX15 | |
| SCHEMBL28836247 | 0.83 | KMT2A (0.42) | KMT2AFOLH1CA2CA1RIMKLA | |
| SCHEMBL28836244 | 0.83 | KMT2A (0.42) | KMT2AFOLH1CA2CA1RIMKLA | |
| Hydrochloric Acid SCHEMBL28220853 | 0.82 | FOLH1 (0.46) | KMT2AFOLH1CA2CA1RIMKLA | |
| SCHEMBL27623042 | 0.81 | FOLH1 (0.50) | KMT2AFOLH1CA2CA1RIMKLA | |
| SCHEMBL21538566 | 0.81 | FOLH1 (0.51) | KMT2AFOLH1CA2CA1RIMKLA | |
| SCHEMBL18190841 | 0.81 | FOLH1 (0.51) | KMT2AFOLH1CA2CA1RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| US-9487500-B2 | Compounds and compositions thereof | INHIBIKASE THERAPEUTICS, INC. (US) | 2016-11-08 | — | — | US | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| EP-2903979-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | Inhibikase Therapeutics, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | claimed |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| WO-2014055938-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200046699-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3532066-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Inhibikase Therapeutics, Inc. (US) | 2019-09-04 | — | — | EP | disclosed |
| WO-2018081251-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-9907796-B2 | Methods of treating tumoral diseases, or bacterial or viral infections | INHIBIKASE THERAPEUTICS, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-2903979-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | Inhibikase Therapeutics, Inc. (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | disclosed |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| WO-2014055938-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | TPMT, BHMT2, PFAS | KMT2A 645/4885FOLH1 35/4885CA2 3448/4885 |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | POLI, MCL1, HRAS | KMT2A 3522/4885FOLH1 1253/4885CA2 4709/4885 |
| US-20200046699-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | ABL1, FYN, PTK2 | KMT2A 1149/4885FOLH1 3896/4885CA2 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.